The Fluxergy Test Kit COVID-19, which utilizes state-of-the-art Sample-to-Answer-RT-PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in one hour. This device is solely intended to be used by healthcare professionals. Results were obtained from internal performance evaluation using clinical samples benchmarked against an FDA-EUA approved method.
FAST PCR: DETECT SARS-COV-2
IN ONE HOUR
Do you need more information?
UNIQUELY POSITIONED TO
TRANSFORM POINT-OF-CARE TESTING
Issues in Diagnostic Testing Today
Current diagnostic testing methodology is too slow and too inaccessible to address today’s dramatically changing healthcare challenges. There is an immediate need for technologies that provide fast, accurate, and low-cost tests directly at the Point of Care. Historically, Point-of-Care Testing has struggled with accuracy, cost, and ease-of-use.
Our Vision of the Future
Fluxergy is building a future where testing is simple, the barriers to testing are reduced, and where limitless testing is accessible to everyone.
These issues can be addressed with a small analyzer which can:
ABOUT THE FLUXERGY
THE ANALYZER SYSTEM
Fluxergy’s simple workflow on a compact analyzer makes it ideal for use in laboratory or field settings. Potential environments for rapid testing applications include emergency rooms, outpatient procedures, urgent care, workplace screening, mobile testing, and community level testing settings. This device is solely intended to be used by healthcare professionals.
Designed to deliver test results within one hour (15-60 minutes depending on the test). The Fluxergy Testing System consists of:
Fluxergy Works software
WHAT EXPERTS SAY ABOUT THE
FLUXERGY ANALYZER SYSTEM
“Two things about the Fluxergy system stand out, especially in the case of a viral pandemic: its accuracy using RT-PCR technology and its ability to deliver results in 1 hour at the point-of-care. When someone is in the emergency room and a person is coughing, you want to confidently know right away what that person has, whether its COVID-19 or Influenza.”
– Dr. David Smith, MD, MAS, FACP, FIDSA
Professor of Medicine, Head of the UCSD Division of Infectious Diseases And Global Public Health Member of Fluxergy’s Advisory Board